Class: Use (276)
Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
Patent Number: 7,153,501It is known that various hematopoietic cells are involved in the ocular injury caused by uncontrolled angiogenesis. This occurs, for example, in wet macular degeneration, a disease in which antiangiogeneic agents are clinically used successfully. Since hematopoietic lineage cells are known to enter the ocular areas and assist in angiogenesis, the inventors asked why not use these cells as a...
Placental growth factor as a target for the treatment of osteoporosis
Patent Number: 7,357,929This patent covers the inhibition of placental growth factor as a method of treating osteoporosis. The one issued claim is restricted to inhibition of placental growth factor using an antibody or fragments of the antibody.
The inventor demonstrated inhibition of bone resorption in an animal model, as well as in vitro using anti-placental growth factor antibodies...
1 Comment
Fish produced by nuclear transfer from cultured cells
Patent Number: 7,332,647One may notice that many of the patents in the StemCellPatents.com database direct their claims towards "mammals" here is one exception. The current patent is directed towards cloning of fish. The inventors state that nuclear transfer in fish was actually performed since the 1960s, however despite much work in the area, this is the first time that cultured cells are used as nucleus donors...
Method of judging leukemia, pre-leukemia or aleukemic malignant blood disease and diagnostic therefor
Patent Number: 7,479,371This patent covers the use of stem cell growth factor concentrations as a means of diagnosing a leukemic condition.
The main coverage of the patent is represented in the first independent claim, which covers:
"A method for diagnosing leukemia, pre-leukemia or aleukemic malignant blood diseases wherein stem cell growth factor (SCGF) in an in-vivo sample is quantified... This patent is a continuation of Blasticon's #7,138,275 covering a monocyte-derived stem cell that is capable of differentiating into islets, hepatocytes, and neurons. In the current patent the use of hepatic, or hepatic-like cells derived from these monocytes is covered. The general coverage of the patent extends to generation and use of a cell... Trangenic animals have been very useful in the basic sciences in terms of elucidating biological activities of specific proteins in an in vivo situation. In terms of developing therapeutics, transgenic animals are useful for a wide variety of practical purposes ranging from in vivo production of recombinant proteins for human use, to serving as bioincubators for tissue and three-dimensional... Endothelial injury may be induced by numerous means. One clinically relevant situation is endothelial injury caused by balloon injury during percutaneous transluminal coronary balloon angioplasty. This injury causes restenosis, which eventually requires re-intervention. This patent teaches ways of accelerating the healing of the injured tissue by essentially “sticking” the endothelial... Non-healing bone injuries pose a significant burden on our medical system. This new patent owned by the Kensey Nash Corporation provides a novel method for accelerating bone healing through providing an implantable matrix that contains collagen and "osteoinductive" factors. These factors may be proteins or cells according to the invention.
The first independent claim of the patent covers... The use of erythropoietin for non-hematopoietic purposes has been increasing in the last couple of years. One obvious example is the Canadian company Stem Cell Therapeutics (sss.v) which is using erythropoietin together with human chorionic gonadotropin for treatment of patients post-stroke. Other uses of erthrypoietin include direct
Dedifferentiated, programmable stem cells of monocytic origin, and their production and use
Patent Number: 7,553,663
Chimeric bird from embryonic stem cells
Patent Number: 7,145,057
1 Comment
Endothelialization of vascular surfaces
Patent Number: 7,172,758
Devices and methods for treating defects in the tissue of a living being
Patent Number: 7,166,133
Use of erythropoietin for the preventive or curative treatment of cardiac failure
Patent Number: 7,335,490
Longevity and PAPP-A
Patent Number: 7,402,724Pregnancy associated plasma protein-A (PAPP-A) is a protease that cleaves insulin-like growth factor binding-protein (IGFBP-4). PAPP-A is used experimentally as a diagnostic for myocardial infarction and also is indicative of various congenital abnormalities in utero.
Interestingly, if PAPP-A is knocked out or functionally inactivated in mice, there is reduced levels of IGF activity...